@TheDermEditor profile picture
The Dermatologist @TheDermEditor

Providing current insights and peer perspectives into today's dermatology issues and news

Joined October 2009
  • Tweets 4,516
  • Following 1,525
  • Followers 17,976
1,101 Photos and videos
When does lichen planus need escalation? Melissa Mauskar centers symptom burden, chronicity, and quality-of-life impact. #LichenPlanus #DermTwitter hubs.ly/Q04jpwxz0

Lichen Planus and Lichenoid Dermatoses

Dr Melissa Mauskar discusses when to escalate treatment in chronic or refractory lichen planus based on quality-of-life impact and symptom burden.

hmpgloballearningnetwork.com
1
58
GLP-1 weight loss is changing body contouring consults: laxity, volume change, timing, and patient expectations. Natasha A. Mesinkovska, MD, PhD #GLP1 #DermTwitter hubs.ly/Q04jpPk-0

Body Contouring in the Age of GLP-1

Dr Natasha Mesinkovska discusses how rapid weight loss associated with GLP-1 receptor agonists is reshaping body contouring in aesthetic dermatology.

hmpgloballearningnetwork.com
69
CLE pipeline update: litifilimab, anifrolumab, TYK2 inhibitors, TLR7/8 antagonists—and the systemic risk conversation. Joseph Merola. #Lupus #DermTwitter hubs.ly/Q04jrPLx0

Cutaneous Lupus Erythematosus: Pipeline Updates, Systemic Risk, and Shared Decision-Making

Dr Joseph Merola highlights major advances in the cutaneous lupus erythematosus (CLE) pipeline, including targeted therapies such as litifilimab, anifrolumab, TYK2 inhibitors, and TLR7/8 antagonists.

hmpgloballearningnetwork.com
100
Trusted lasers, vascular devices, resurfacing tools—and what comes next in 2026. Omar A. Ibrahimi, MD, PhD shares his device outlook. #LaserDermatology #DermTwitter hubs.ly/Q04jpXlW0

Devices I Can’t Live Without and What I’m Excited About in 2026

In this expert Q&A, Dr Ibrahimi offers insight into energy-based technologies from trusted lasers for resurfacing and vascular conditions to emerging advancements like focal point technology.

hmpgloballearningnetwork.com
86
Advanced NMSC update: ✔️ Hedgehog inhibitors for BCC ✔️ PD-1 therapy for CSCC ✔️ New combo neoadjuvant strategies emerging Precision oncology is here 🔗 hubs.ly/Q04l6sCy0 #DermTwitter #SkinCancer

Innovations in Systemic Therapy for Advanced Nonmelanoma Skin Cancers

Explore the evolving treatment landscape for advanced basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (CSCC).

hmpgloballearningnetwork.com
1
94
Immune-mediated hair loss is changing fast. Emma Guttman on JAK inhibitors, biologics, small molecules, and systemic therapy decisions. #HairLoss #DermTwitter hubs.ly/Q04jq10L0

Update in Immune-Mediated Hair Loss

Dr Emma Guttman discusses advances in understanding immune-mediated hair loss, highlighting how new targeted therapies—including JAK inhibitors, biologics, and other small molecules—are reshaping...

hmpgloballearningnetwork.com
1
99
Buy-and-bill may improve access and practice control in dermatology—but workflow and operations matter. Mark D. Kaufmann, MD #PatientAccess #DermTwitter hubs.ly/Q04jpTN_0

Buy-and-Bill Model May Improve Access and Practice Control in Dermatology

The buy-and-bill reimbursement model may provide dermatology practices with greater control over treatment delivery, faster patient access to therapy, and potential operational advantages.

hmpgloballearningnetwork.com
1
61
Major sunscreen update ☀️ FDA approves bemotrizinol (Tinosorb S)—the first new OTC sunscreen filter in 20 years. Conversation with Dr Jane Yoo ✔️ UVA1 UVB protection ✔️ Photostable ✔️ Great for melasma & skin of color hubs.ly/Q04l4R-h0 #DermTwitter #Sunscreen

FDA Approves Bemotrizinol: What Dermatologists Need to Know

The Dermatologist spoke with Dr Jane Yoo about the FDA’s landmark approval of bemotrizinol. Dr Yoo discusses how this photostable, broad-spectrum UV filter may improve UVA protection, expand cosmet...

hmpgloballearningnetwork.com
1
103
Systemic sclerosis care is evolving: antifibrotics, vascular targets, and CAR-T immune reset strategies. Scott Elman explains. #SystemicSclerosis #DermTwitter hubs.ly/Q04jpnSG0

Systemic Sclerosis: Emerging Treatments

What’s next in systemic sclerosis care? Dr Scott Elman explores the evolving treatment landscape—from antifibrotic and vascular-targeted therapies to CAR-T–based immune reset strategies.

hmpgloballearningnetwork.com
71
From injector to owner: procedural skill is only the starting point. Elisabeth Smith, PA-C on operations, finances, and readiness. #AestheticBusiness #DermTwitter hubs.ly/Q04jp8Yh0

From Injector to Owner: Aesthetic Business Growth Requires Operational and Financial Readiness

Launching an aesthetic practice requires a significant shift from procedural expertise to operational leadership.

hmpgloballearningnetwork.com
76
FDA update 🚨 Lebrikizumab (EBGLYSS) now offers: ✔️ Every-8-week maintenance dosing ✔️ As few as 6 injections/year ✔️ No new safety signals More flexibility for AD care 🔗 hubs.ly/Q04kMVVK0 #DermTwitter #AtopicDermatitis

FDA Approves Every-8-Week Maintenance Dosing Option for Lebrikizumab in Atopic Dermatitis

The FDA approved an every-8-week maintenance dosing regimen for EBGLYSS (lebrikizumab-lbkz), providing a new administration option for adults and adolescents aged 12 years and older weighing at least...

hmpgloballearningnetwork.com
96
Cutaneous irAEs can affect cancer treatment continuity. Megan Heberton on grading, management, and the dermatologist’s role. #Oncodermatology #DermTwitter hubs.ly/Q04jrM8W0

Cutaneous Immune-Related Adverse Events and Checkpoint Inhibitors

This interview explores the most common cutaneous immune-related adverse events seen with immune checkpoint inhibitors and how dermatologists can grade and manage toxicity while supporting continua...

hmpgloballearningnetwork.com
89
NP-owned aesthetic practices face state-by-state variation in supervision, delegation, and liability risk. Haley Wood, NP #AestheticPractice #DermTwitter hubs.ly/Q04jpD7l0

NP-Owned Aesthetic Practices Face Expanding Regulatory and Liability Challenges

Regulatory oversight of nurse practitioner (NP)-owned aesthetic practices remains highly variable across states, creating legal and operational risks related to supervision, delegation, and malprac...

hmpgloballearningnetwork.com
1
75
Better UVA coverage, photostability, and cosmetic elegance can all shape sunscreen adherence. Jane Yoo on what’s new in filters. #Sunscreen #DermTwitter hubs.ly/Q04jr_HS0

Sunscreen Filters: What’s New in UVA Protection, Formulations, and Global Options

Explore the latest advances in sunscreen filter technology, including improved UVA coverage, photostability, and cosmetic formulations that enhance patient adherence.

hmpgloballearningnetwork.com
58
Operational resilience in dermatology depends on scalable systems, layered care, and proactive patient engagement. Ava Shamban, MD #PracticeManagement #DermTwitter hubs.ly/Q04jpyY30

Operational Flexibility and Layered Care Strategies Drive Practice Resilience in Dermatology

Scalable systems, proactive patient engagement, and integrated treatment strategies may strengthen both clinical outcomes and operational resilience in dermatology practices.

hmpgloballearningnetwork.com
73
Outcome measures can bias care. Oyetewa Asempa Andrew Alexis on inclusive trial design, terminology, and equitable severity assessment. #SkinOfColor #DermTwitter hubs.ly/Q04jrLjP0

Advancing Inclusive Outcome Measures in Dermatology

In a recent panel discussion, Dr Asempa and Dr Alexis emphasized that without inclusive trial design and culturally responsive terminology, we risk biased severity assessments and inequitable...

hmpgloballearningnetwork.com
125
Practice sales require more than a buyer. Ellen Marmur, MD on planning, valuation, team alignment, and protecting clinical culture. #PracticeManagement #DermTwitter hubs.ly/Q04jp4fx0

Strategic Planning and Team Alignment Are Central to Successful Practice Sales

Selling a dermatology practice requires long-term planning, financial analysis, and careful alignment between physicians, staff, and investors.

hmpgloballearningnetwork.com
87
HS care starts before severe disease: early recognition, faster referral, and medical-surgical coordination. Jack O’Brien, Alice Gottlieb, Dennis Orgill. #HidradenitisSuppurativa #DermTwitter hubs.ly/Q04js3zV0

Reimagining Hidradenitis Suppurativa Care: Early Recognition, Therapeutic Innovation, and Multidi...

During an expert discussion, speakers emphasized that improving outcomes in HS requires earlier recognition, reduction of diagnostic delay, coordinated referral systems, and integration of medical...

hmpgloballearningnetwork.com
132
Microneedling RF offers non-chromophore-dependent remodeling for scars and skin texture. Catherine M. DiGiorgio, MD, MS, FAAD #MicroneedlingRF #DermTwitter hubs.ly/Q04jpcQL0

Microneedling Radiofrequency Evolves as a Versatile Option for Skin Remodeling

Microneedling with radiofrequency continues to expand within procedural dermatology, offering a non-chromophore-dependent approach to skin remodeling and scar treatment.

hmpgloballearningnetwork.com
1
127
Dermatomyositis is systemic, heterogeneous, and evolving. Victoria Werth Scott Elman on organ involvement, autoantibodies, and novel therapies. #Dermatomyositis #DermTwitter hubs.ly/Q04jqpYm0

Advances in Dermatomyositis: The Evolving Landscape and Potential Role of Novel Therapies to...

Dermatomyositis is a systemic autoimmune myopathy with prominent cutaneous features and significant heterogeneity across organ involvement, autoantibody profiles, and disease course.

hmpgloballearningnetwork.com
111
Load more